6.66 USD
-0.51 (-7.11%)
6.55 USD
-0.11 (-1.65%)
We assign a fundamental rating of 4 out of 10 to BCRX. BCRX was compared to 525 industry peers in the Biotechnology industry. There are concerns on the financial health of BCRX while its profitability can be described as average. BCRX has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- In the past year BCRX has reported negative net income.
- BCRX had a positive operating cash flow in the past year.
- In the past 5 years BCRX always reported negative net income.
- In the past 5 years BCRX always reported negative operating cash flow.
1.2 Ratios
- BCRX has a Return On Assets of -1.97%. This is amongst the best in the industry. BCRX outperforms 87.62% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 23.47%, BCRX belongs to the top of the industry, outperforming 98.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.97% | ||
| ROE | N/A | ||
| ROIC | 23.47% |
ROA(3y)-35.62%
ROA(5y)-38.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- BCRX has a better Operating Margin (12.69%) than 92.38% of its industry peers.
- BCRX has a better Gross Margin (97.39%) than 96.95% of its industry peers.
- In the last couple of years the Gross Margin of BCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.69% | ||
| PM (TTM) | N/A | ||
| GM | 97.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.65%
GM growth 5Y1.2%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BCRX is creating value.
- The number of shares outstanding for BCRX has been increased compared to 1 year ago.
- The number of shares outstanding for BCRX has been increased compared to 5 years ago.
- The debt/assets ratio for BCRX is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -2.14, we must say that BCRX is in the distress zone and has some risk of bankruptcy.
- BCRX's Altman-Z score of -2.14 is in line compared to the rest of the industry. BCRX outperforms 50.29% of its industry peers.
- The Debt to FCF ratio of BCRX is 20.43, which is on the high side as it means it would take BCRX, 20.43 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 20.43, BCRX belongs to the top of the industry, outperforming 90.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 20.43 | ||
| Altman-Z | -2.14 |
ROIC/WACC2.99
WACC7.85%
2.3 Liquidity
- BCRX has a Current Ratio of 1.87. This is a normal value and indicates that BCRX is financially healthy and should not expect problems in meeting its short term obligations.
- The Current ratio of BCRX (1.87) is worse than 77.33% of its industry peers.
- BCRX has a Quick Ratio of 1.83. This is a normal value and indicates that BCRX is financially healthy and should not expect problems in meeting its short term obligations.
- BCRX has a Quick ratio of 1.83. This is in the lower half of the industry: BCRX underperforms 76.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.87 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 94.83% over the past year.
- BCRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 45.38%.
- Measured over the past years, BCRX shows a very strong growth in Revenue. The Revenue has been growing by 55.99% on average per year.
EPS 1Y (TTM)94.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%185.71%
Revenue 1Y (TTM)45.38%
Revenue growth 3Y42.06%
Revenue growth 5Y55.99%
Sales Q2Q%36.14%
3.2 Future
- The Earnings Per Share is expected to grow by 41.76% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 19.11% on average over the next years. This is quite good.
EPS Next Y131.13%
EPS Next 2Y67.74%
EPS Next 3Y46.5%
EPS Next 5Y41.76%
Revenue Next Year37.36%
Revenue Next 2Y20.37%
Revenue Next 3Y17.28%
Revenue Next 5Y19.11%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- BCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- A Price/Forward Earnings ratio of 19.04 indicates a rather expensive valuation of BCRX.
- Based on the Price/Forward Earnings ratio, BCRX is valued cheaper than 93.90% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of BCRX to the average of the S&P500 Index (24.29), we can say BCRX is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 19.04 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BCRX indicates a rather cheap valuation: BCRX is cheaper than 93.71% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, BCRX is valued cheaper than 92.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.47 | ||
| EV/EBITDA | 22.41 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- BCRX's earnings are expected to grow with 46.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y67.74%
EPS Next 3Y46.5%
5. Dividend
5.1 Amount
- BCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
6.66
-0.51 (-7.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-12 2026-01-12/amc
Earnings (Next)05-04 2026-05-04/bmo
Inst Owners101%
Inst Owner Change-0.97%
Ins Owners0.81%
Ins Owner Change12.31%
Market Cap1.40B
Revenue(TTM)599.82M
Net Income(TTM)-8.78M
Analysts84
Price Target20.91 (213.96%)
Short Float %18.85%
Short Ratio9.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)123.57%
Min EPS beat(2)67.02%
Max EPS beat(2)180.11%
EPS beat(4)3
Avg EPS beat(4)55.88%
Min EPS beat(4)-123.6%
Max EPS beat(4)180.11%
EPS beat(8)5
Avg EPS beat(8)36.47%
EPS beat(12)7
Avg EPS beat(12)16.41%
EPS beat(16)10
Avg EPS beat(16)18.04%
Revenue beat(2)1
Avg Revenue beat(2)1.42%
Min Revenue beat(2)-4.11%
Max Revenue beat(2)6.96%
Revenue beat(4)2
Avg Revenue beat(4)3.6%
Min Revenue beat(4)-4.11%
Max Revenue beat(4)12.47%
Revenue beat(8)6
Avg Revenue beat(8)4.18%
Revenue beat(12)7
Avg Revenue beat(12)2.45%
Revenue beat(16)7
Avg Revenue beat(16)1.1%
PT rev (1m)-0.66%
PT rev (3m)16.24%
EPS NQ rev (1m)18.13%
EPS NQ rev (3m)46.38%
EPS NY rev (1m)0.76%
EPS NY rev (3m)93.05%
Revenue NQ rev (1m)-0.36%
Revenue NQ rev (3m)-3.25%
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)-1.11%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 19.04 | ||
| P/S | 2.34 | ||
| P/FCF | 42.47 | ||
| P/OCF | 39.66 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 22.41 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.35
Fwd EY5.25%
FCF(TTM)0.16
FCFY2.35%
OCF(TTM)0.17
OCFY2.52%
SpS2.85
BVpS-1.84
TBVpS-1.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.97% | ||
| ROE | N/A | ||
| ROCE | 29.7% | ||
| ROIC | 23.47% | ||
| ROICexc | 138.79% | ||
| ROICexgc | 138.79% | ||
| OM | 12.69% | ||
| PM (TTM) | N/A | ||
| GM | 97.39% | ||
| FCFM | 5.5% |
ROA(3y)-35.62%
ROA(5y)-38.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.65%
GM growth 5Y1.2%
F-Score5
Asset Turnover1.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 20.43 | ||
| Debt/EBITDA | 8.21 | ||
| Cap/Depr | 179.53% | ||
| Cap/Sales | 0.39% | ||
| Interest Coverage | 2.31 | ||
| Cash Conversion | 45.68% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.87 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | -2.14 |
F-Score5
WACC7.85%
ROIC/WACC2.99
Cap/Depr(3y)104.99%
Cap/Depr(5y)137.87%
Cap/Sales(3y)0.47%
Cap/Sales(5y)1.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%185.71%
EPS Next Y131.13%
EPS Next 2Y67.74%
EPS Next 3Y46.5%
EPS Next 5Y41.76%
Revenue 1Y (TTM)45.38%
Revenue growth 3Y42.06%
Revenue growth 5Y55.99%
Sales Q2Q%36.14%
Revenue Next Year37.36%
Revenue Next 2Y20.37%
Revenue Next 3Y17.28%
Revenue Next 5Y19.11%
EBIT growth 1Y286.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year560.51%
EBIT Next 3Y115.54%
EBIT Next 5YN/A
FCF growth 1Y129.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y132.12%
OCF growth 3YN/A
OCF growth 5YN/A
BIOCRYST PHARMACEUTICALS INC / BCRX FAQ
Can you provide the ChartMill fundamental rating for BIOCRYST PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 4 / 10 to BCRX.
What is the valuation status for BCRX stock?
ChartMill assigns a valuation rating of 6 / 10 to BIOCRYST PHARMACEUTICALS INC (BCRX). This can be considered as Fairly Valued.
How profitable is BIOCRYST PHARMACEUTICALS INC (BCRX) stock?
BIOCRYST PHARMACEUTICALS INC (BCRX) has a profitability rating of 4 / 10.